Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · SPDR (State Street)

State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF (XPH)

Ticker XPH · Index fund · · Holdings as of Jun 30, 2026

Expense ratio
0.35%$35/yr per $10k
5-yr return
+2.8%annualized
1-yr return
+31.6%as of Dec 2025
Net assets
$428.4Mall share classes
Holdings
67

Bottom line

Is XPH a good fund? The bottom line

XPH is an index health care sector ETF from SPDR (State Street).

It charges 0.35% — about $35 a year on every $10,000 invested, cheaper than 91% of health care sector funds we track.

It returned +31.6% over one year, +2.8% a year over five years, +1.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $428 million in net assets and 67 holdings, its largest position is State Street Global Advisors (8.6%) and the top 10 make up 28.9% of the portfolio.

What stands out

  • Low cost: cheaper than 91% of health care sector peers

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What XPH invests in

The State Street SPDR S&P Pharmaceuticals ETF (the Fund) seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index.

In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index ? (the Index), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund. Based on its analysis of these factors, SSGA Funds Management, Inc. (SSGA FM or the Adviser), the investment adviser to the Fund, either may invest the Fund's assets in a subset of securities in the Index or may invest the Fund's assets in substantially all of the securities represented in the Index in approximately the same proportions as the Index, as…

From the fund's prospectus (filed Oct 26, 2026).

XPH performance

Fund calendar-year total returns, 2015–2025 2015: +1.5%; 2016: −23.2%; 2017: +12.0%; 2018: −15.2%; 2019: +25.7%; 2020: +14.4%; 2021: −10.5%; 2022: −9.8%; 2023: +2.9%; 2024: +5.1%; 2025: +31.6% +2% 2015 −23% 2016 +12% 2017 −15% 2018 +26% 2019 +14% 2020 −11% 2021 −10% 2022 +3% 2023 +5% 2024 +32% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
XPH+31.6%+2.8%+1.9%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full XPH performance history →

What XPH costs

On a $10,000 investment, XPH's 0.35% expense ratio costs about $35 a year. The prospectus estimates $443 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full XPH fee table →

XPH top 10 holdings

#Holding% of fund
1State Street Global Advisors8.58%
2Definium Therapeutics Inc3.09%
3MBX Biosciences Inc2.72%
4Alumis Inc2.14%
5AtaiBeckley Inc2.13%
6Trevi Therapeutics Inc2.12%
7Enliven Therapeutics Inc2.09%
8Amylyx Pharmaceuticals Inc2.04%
9VeraDermics Inc2.02%
10Ligand Pharmaceuticals Inc1.94%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 28.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to XPH

More funds like XPH →

XPH FAQ

What is the expense ratio of XPH?
XPH's expense ratio is 0.35%, which works out to about $35 a year for every $10,000 invested. The prospectus estimates total costs of $443 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is XPH a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 91% of health care sector peers; 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does XPH hold?
XPH's largest holdings are State Street Global Advisors (8.6%), Definium Therapeutics Inc (3.1%), MBX Biosciences Inc (2.7%), Alumis Inc (2.1%), AtaiBeckley Inc (2.1%). It holds 67 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is XPH's 5-year return?
XPH returned +2.8% a year over the five years ending Dec 31, 2025, and +1.9% a year over ten years. Past performance does not guarantee future results.
Who manages XPH?
XPH is offered by SPDR (State Street) through Spdr Series Trust.